Conceptus to Present at A.G. Edwards 2nd Annual Emerging Growth Conference 2007

Business Wire, Sept 13, 2007

MOUNTAIN VIEW, Calif. -- Conceptus, Inc. (NASDAQ:CPTS) announces that Mark Sieczkarek, president and chief executive officer, will present at A.G. Edwards' 2nd Annual Emerging Growth Conference 2007 on Wednesday, September 19, at 9:00 a.m. ET. The conference will be held at the New York Palace Hotel in New York from September 18 - September 19, 2007.

A live webcast of the presentation will be available by going to www.conceptus.com and clicking on the link to Live Webcasts. An archived replay will be available for a period of 30 days.

About the Essure([R]) Procedure

The Essure procedure, approved by the FDA in 2002, is a sterilization procedure that replaces tubal ligation for women. A soft micro-insert is placed into the Fallopian tubes through the cervix using a hysteroscope. Once in place, the device is designed to elicit tissue growth in and around the micro-insert to form an occlusion or blockage in the Fallopian tubes, over three months. An Essure procedure does not require cutting into the body and can be performed in the doctor's office, a less costly procedure setting, with just a local anesthetic. A woman is able to leave the office about 45 minutes after the procedure is completed. The Essure confirmation test is performed three months after the procedure to confirm that the micro-inserts are in the correct location, the tubes are blocked and that the woman can discontinue temporary birth control. The Essure procedure is 99.80% effective (based on four years of clinical study follow-up data). The probability of pregnancy in 1000 women at 4 years is only 2.0 as compared to 11.8 for surgical tubal ligation procedures studied in CREST.

About Conceptus

Conceptus, Inc. manufactures and markets the Essure Permanent Birth Control system, an innovative medical device and procedure designed to provide a non-incisional alternative to tubal ligation, which is currently the leading form of birth control worldwide. The availability of the Essure procedure in the U.S. is expected to open up a market currently occupied by incisional tubal ligation and vasectomy, which combined account for more than 1 million procedures annually.

Additional information about the Essure procedure is available at www.essure.com or by calling the Essure Information Center at 1-877-ESSURE1. Additional information about Conceptus is available at www.conceptus.com or by calling 1-877-ESSURE2.